• Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reported a quarterly EPS of -$5.08, missing the estimated EPS of -$2.04.
• The company's revenue for the quarter was $287.3 million, surpassing the estimated $244.96 million, with Rezdiffra™ net sales contributing significantly to this growth.
• Madrigal has strengthened its market position through strategic initiatives, including a global licensing agreement and the launch of Rezdiffra in Germany, alongside maintaining a strong current ratio of 5.11 and cash reserves of $1.1 billion.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company focused on developing innovative therapies for cardiovascular and metabolic diseases. The company is known for its product Rezdiffra™ (resmetirom), which has gained traction in the market. Despite its promising product lineup, Madrigal faces competition from other pharmaceutical companies in the same therapeutic area.

On November 4, 2025, Madrigal reported its earnings, revealing an EPS of -$5.08, which was significantly below the estimated EPS of -$2.04. This quarterly loss was a slight increase from the $4.92 per share loss reported in the same quarter last year. Despite the earnings miss, the company has a history of surpassing consensus EPS estimates in three of the past four quarters.

Madrigal's revenue for the quarter was $287.3 million, exceeding the estimated $244.96 million and showing a substantial increase from the $62.17 million reported a year ago. This revenue growth highlights the company's ability to generate higher sales, particularly from its product Rezdiffra, which recorded net sales of $287.3 million. Over 29,500 patients are currently using Rezdiffra, indicating strong market acceptance.

The company has also made strategic moves to strengthen its pipeline and market position. Madrigal entered a global licensing agreement with CSPC Pharma to incorporate an oral GLP-1 into its offerings. Additionally, a new Orange Book listed patent for Rezdiffra extends its protection until 2045. The launch of Rezdiffra in Germany following European Commission approval further expands its market reach.

Financially, Madrigal has a negative P/E ratio of -35.13, reflecting its current lack of profitability. However, with a strong current ratio of 5.11, the company demonstrates a good ability to cover short-term liabilities. Madrigal's cash reserves, totaling $1.1 billion, provide a solid financial foundation to support its ongoing operations and strategic initiatives.